| Basics |
Prothena Corporation plc Ordinary Shares
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.
|
| IPO Date: |
December 21, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$246.53M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.90 | 2.91%
|
| Avg Daily Range (30 D): |
$0.22 | 2.93%
|
| Avg Daily Range (90 D): |
$0.36 | 3.07%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.36M |
| Avg Daily Volume (30 D): |
1.72M |
| Avg Daily Volume (90 D): |
.82M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
123 |
| Avg Trade Size (Sh.) (90 D): |
93 |
| Institutional Trades |
| Total Inst.Trades: |
3,380 |
| Avg Inst. Trade: |
$1.88M |
| Avg Inst. Trade (30 D): |
$1.85M |
| Avg Inst. Trade (90 D): |
$1.34M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.23M |
| Avg Closing Trade (30 D): |
$1.23M |
| Avg Closing Trade (90 D): |
$1.01M |
| Avg Closing Volume: |
66.45K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-2.05
|
$-1.12
|
$-1.07
|
|
Diluted EPS
|
$-2.07
|
$-1.12
|
$-1.07
|
|
Revenue
|
$ 137.94M
|
$ 2.83M
|
$ 2.12M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -110.27M
|
$ -60.2M
|
$ -57.96M
|
|
Operating Income / Loss
|
$ -138.61M
|
$ -65.58M
|
$ -64.9M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -129.93M
|
$ -53.45M
|
$ -47.87M
|
|
PE Ratio
|
|
|
|
|
